Tamsulosin MR and OCAS (modified release and oral controlled absorption system): Current therapeutic uses

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 5, 2008, Pages 813-824

  Nargund, Vinod H ^a,b   Grey, Alistair D R ^c  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b HOMERTON UNIVERSITY HOSPITAL   (United Kingdom)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

1 adrenoceptor antagonists; 1 adrenoceptors; Benign prostatic hyperplasia; Lower urinary tract symptoms; Tamsulosin

Indexed keywords

5 METHYLURAPIDIL; ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 1A ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CIMETIDINE; CIPROFLOXACIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; ESTROGEN; FINASTERIDE; INDORAMIN; PHENOXYBENZAMINE; PHENYLEPHRINE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PRAZOSIN; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN; TESTOSTERONE; TOLTERODINE; WARFARIN; SULFONAMIDE;

ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE; BRACHYTHERAPY; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONTROLLED DRUG RELEASE; DIZZINESS; DRUG ABSORPTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG WITHDRAWAL; EJACULATION DISORDER; FATIGUE; HUMAN; HYPERTENSION; HYPOTENSION; IRIS DISEASE; LOWER URINARY TRACT SYMPTOM; MONOTHERAPY; NEPHROLITHIASIS; NONHUMAN; ORTHOSTATIC HYPOTENSION; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATITIS; PROTEIN SYNTHESIS INHIBITION; PULSE RATE; QUESTIONNAIRE; RETROGRADE EJACULATION; REVIEW; SCORING SYSTEM; SIDE EFFECT; STRUCTURE ANALYSIS; SUSTAINED RELEASE FORMULATION; SYMPATHETIC INNERVATION; TRANSURETHRAL RESECTION; URETHRA STONE; URINE RETENTION; UROGENITAL SYSTEM; UROGENITAL TRACT DISEASE; DELAYED RELEASE FORMULATION; DRUG EFFECT; FEMALE; MALE; METABOLISM; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADRENERGIC ALPHA-ANTAGONISTS; CLINICAL TRIALS AS TOPIC; DELAYED-ACTION PREPARATIONS; FEMALE; FEMALE UROGENITAL DISEASES; HUMANS; MALE; MALE UROGENITAL DISEASES; PROSTATIC HYPERPLASIA; RECEPTORS, ADRENERGIC, ALPHA-1; SULFONAMIDES;

EID: 41949129155     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.5.813     Document Type: Review

References (89)

1. McNeal JE. Origin and evolution of benign prostatic enlargement. J Urol 1978;15(4):340-5
2. Connolly SS, Fitzpatrick JM. Review: medical treatment of benign prostatic hyperplasia. Postgrad Med J 2007;83:73-8
3. Garraway WM, Russell EB, Lee RJ, et al. Impact of previously unrecognized benign prostatic hyperplasia on the daily activities of middle-aged and elderly men. Br J Gen Pract 1993;43(373):318-21
4. Verhamme KM, Dieleman JP, Bleumink GS, et al.; The Triumph Pan European Expert Panel. Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care - the Triumph project. Eur Urol 2002;42(4):323-8
5. Abrams P. Nocturia: a major problem in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction (LUTS/BPO). Eur Urol 2005;3(6):8-16
6. Jepsen JV, Bruskewitz RC. Comprehensive patient evaluation for benign prostatic hyperplasia. Urology 1998;51(4A Suppl):13-8
7. Mebust W, Roizo R, Schroeder F, Villiers A. Correlation between pathology. clinical symptoms and the course of the disease. In: The International Consultation on Benign Prostatic Hyperplasia (BPH). Cockett ATK, Aso Y, Chatelain C, et al. editors. Geneva: WHO; 1991. p. 53-62
8. Madsen PO, Iverson P. A point system for selecting operative candidates. In: Hinman F Jr. (Ed) Benign Prostatic Hypertrophy. New York: Springer 1983:763-5
9. Hansen BJ, Mortensen S, Mensink HJ, et al. Comparison of the Danish prostatic symptom score with the International Prostatic Symptom Score, the Madsen-Iversen and Boyarsky symptom indexes. Br J Urol 1998;81(1):36-41
10. Muller HR, Oberholzer M, Rohr HP, Bartsch G. Light microscopic stereological analysis of the normal human prostate and of benign prostatic hyperplasia. J Urol 1979;122(4):487-91
11. Lepor H, Tang R, Shapiro E. The alpha-adrenoceptor subtype mediating the tension of human prostatic smooth muscle. Prostate 1993;22(4):301-7
12. Parsons JK, Carter HB, Partin AW, et al. Metabolic factors associated with benign prostaric hyperplasia. J Clin Endocrinol Metab 2006;91(7):2562-8
13. Reiter E, Hennuy B, Bruyninx M, et al. Effects of pituitary hormones on the prostate. Prostate 1999;38:159-65
14. Fitzpatrick JM. The natural history of benign prostatic hyperplasia. BJU Int 2006;97(Suppl 2):3-6
15. Chute CG, Panser LA, Girman CJ, et al. The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol 1993;150(1):85-9
16. Jacobsen SJ, Girman CJ, Lieber MM. Natural history of prostatic hyperplasia. Urology 2001;58(Suppl):5-16
17. Meigs JB, Barry MJ, Giovannucci E, et al. Incidence rates and risk factors for acute urinary retention: the health professionals follow-up study. J Urol 1999;162(2):376-82
18. Gosling JA, Dixon JS, Jen PY. The distribution of noradrenergic nerves in the human urinary tract. A review. Eur Urol 1999;36(Suppl 1):23-30
19. Lepor H, Gup DI, Shapiro E. The alpha-adrenoceptor subtype mediating the tension of human prostatic smooth muscle. Prostate 1993;22:301-7
20. Hedlund H, Andersson KE, Larsson B. Alpha-adrenoreceptors and muscarinic receptors in the isolated human prostate. J Urol 1985;134:1291-8
21. Anglin IE, Glassman DT, Kyprianou N. Review: induction of prostate apoptosis by al-adrenoceptor antagonists: mechanistic significance of the quinazoline components. Prost Cancer Prost Dis 2002;5:88-95
22. Hieble JP, Bylund DB, Clarke DE, et al. International Union of Pharmacology. X. Recommendation for nomenclature of alpha 1-adrenoceptors: consensus update. Pharmacol Rev 1995;47(2):267-70
23. Hieble JP, Ruffola RR. The use of alpha-adrenoreceptor antagonists in the management of pharmacological management of benign prostateic hyperplasia: an overview. Pharmacol Res 1996;33(3):145-60
24. Walden PD, Gerardi C, Lepor H. Localization and expression of the alpha1A-1, alpha1B and alpha1D-adrenoceptors in hyperplastic and non-hyperplastic human prostate. J Urol 1999;161(2):635-40
25. Andersson K-E, Gratzke C. Pharmacology of α1-adrenoceptor antagonists in the lower urinary tract and central nervous system. Nature Clin Pract 2007;4(7):368-78
26. Brading AF, McCoy R, Dass N. Alpha1-adrenoceptors in urethral function. Eur Urol 1999;36(Suppl 1):74-9
27. Appell RA, England HR, Hussell AR, McGuire EJ. The effects of epidural anesthesia on the urethral closure pressure profile in patients with prostatic enlargement. J Urol 1980;124(3):410-1
28. Moriyama N, Nasu K, Takeuchi T, et al. Quantifications and distribution of alpha-1A adrenoceptor subtype mRNAs in the human vas deferens: comparison with those of epididymal and pelvic portions. Br J Pharmacol 1997;122:1009-14
29. Furukawa K, Rosario DJ, Smith DJ, et al. Alpha 1A-adrenoceptor-mediated contractile responses of the human vas deferens. Br J Pharmacol 1995;116(1):1605-10
30. Chaturapanich G, Maythaarttaphong S, Verawatnapakul V, Pholpramool C. Mediation of contraction in rat cauda epididymidis by alpha-adrenoceptors. Reproduction 2002;124:887-92
31. Hsieh JT, Chang HC, Law HS, et al. In vivo evaluation of serotonergic agents and α-adrenergic blockers on premature ejaculation by inhibiting the seminal vesicle pressure response to electrical nerve stimulation. Br J Urol 1998;82:237-40
32. Sigala S, Dellabella M, Milanese G, et al. Evidence for the presence of alpha1 adrenoceptor subtypes in the human ureter. Neurourol Urodyn 2005;24(2):142-8
33. Davenport K, Timoney AG, Keeley FX. A comparative in vitro study to determine the beneficial effect of calcium-channel and alpha(1)-adrenoceptor antagonism on human ureteric activity. BJU Int 2006;98(3):651-5
34. Domyanic AV, Morilak DA. Distribution of the alpha 1A adrenergic receptor in the rat brain visualised by in situ hybridisation. J Comp Neurol 1997;386:358-78
35. Day HE, Campeau S, Watson SJ Jr, Akil H. Distribution of alpha 1a, alpha 1b and alpha 1d adrenergic receptor mRNA in the rat brain and spinal cord. J Chem Neuroanat 1997;13:115-39
36. Caine M, Pfau A, Perlberg S. The use of alpha-adrenergic bloclcers in benign prostatic obstruction. Br J Urol 1976;48(4):255-63
37. Caine M, Perlberg S, Meretyk S. A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction. Br J Urol 1978;50:551-4
38. Abrams PH, Shah PJ, Stone R, Choa RG. Bladder outflow obstruction treated with phenoxybenzamine. Br J Urol 1982;54(5):527-30
39. Kirby RS, Coppinger SW, Corcoran MO, et al. Prazosin in the treatment of prostatic obstruction. A placebo-controlled study. Br J Urol 1987;60(2):136-42
40. 1D adrenoceptor subtypes. Br J Pharmacol 1997;120:231-8
41. Kyprianou N, Benning CM. Suppression of human prostate cancer cell growth by α1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis. Cancer Res 2000;60:4550-5
42. Matsushima H, Kamimura H, Soeishi Y, et al. Pharmacokinetics and plasma protein binding of tamsulosin hydrochloride in rats, dogs and humans. Drug Metab Dispos 1998;26(3):240-5
43. Kamimura H, Oishi S, Matsushima H, et al. Identification of cytochrome P450 isozymes involved in metabolism of the alpha1-adrenoceptor blocker tamsulosin in human liver microsomes. Xenobiotica 1998;28(10):909-22
44. Taguchi K, Saitoh M, Sato S, et al. Effects of tamsulosin metabolites at alpha-1 adrenoceptor subtypes. J Pharmacol Exp Ther 1997;280:1-5
45. Narayan P, Tunuguntla HSG. Long-term efficacy and safety of tamsulosin for benign prostatic hyperplasia. Rev Urol 2005;7(4):S42-8
46. Abrams P, Speakman M, Stott M, et al. A dose-ranging study of the efficacy and safety of tamsulosin, the first prostate selective alpha 1A-adrenoceptor antagonist, in patients with benign prostatic obstruction (symptomatic benign prostatic hyperplasia). Br J Urol 1997;80(4):587-96
47. Lepor H. Phase III multicentre placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. Urology 1998;51:892-900
48. Abrams P, Schulman CC, Vaage S; The European Tamsulosin Study Group. Tamsulosin, a selective alpha 1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic 'obstruction' (symptomatic BPH). The European Tamsulosin Study Group. Br J Urol 1995;76(3):325-36
49. Schulman CC, Cortvriend J, Jonas U, et al. Tamsulosin, the first prostate selective alpha 1A-adrenoceptor antagonist. Analysis of a multinational, multi-centre, open-label study assessing the long term efficacy and safety in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group. Eur Urol 1996;29(2):145-54
50. Chapple CR, Wyndaele JJ, Nordling J, et al. Tamsulosin, the first prostate selective alpha 1A-adrenoceptor antagonist. A meta-analysis of two randomised, placebo controlled, multi-centre studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group. Eur Urol 1996;29(2):157-67
51. Chapple CR, Baert L, Thind P, et al. Tamsulosin 0.4 mg once daily: tolerability in older and younger patients with lower urinary tract symptoms suggestive of benign prostatic obstruction (symptomatic BPH). The European Tamsulosin Study Group. Eur Urol 1997;32(4):462-70
52. Lepor H. Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Tamsulosin Investigator Group. Urology 1998;51(6):901-6
53. Narayan P, Lepor H. Long term, open label, phase III multicentre study of tamsulosin in benign prostatic hyperplasia. Urology 2001;57(3):466-70
54. Schulman CC, Lock TM, Buzelin JM, et al.; European Tamsulosin Study Group. Long-term use of tamsulosin to treat lower urinary tract symptoms/ benign prostatic hyperplasia. J Urol 2001;166(4):1358-63
55. Li NC, Chen S, Yang XH, et al.; The Beijing Tamsulosin Study Group. Efficacy of low-dose tamsulosin in chinese patients with symptomatic benign prostatic hyperplasia. Clin Drug Investig 2003;23(12):781-7
56. Park CH, Chang HS, Oh BR, et al. Efficacy of low-dose tamsulosin on lower urinaty tract symptoms suggestive of benign prostatic hyperplasia: a nonblind multicentre Korean study. Clin Drug Investig 2004;24(1):41-7
57. Michel MC, Mehlburger L, Bressel HU, et al. Tamsulosin treatment of 19,365 patients with lower urinary tract symptoms: does co-morbidity alter tolerability? J Urol 1998;160(3 Pt 1):784-91
58. 1-adrenoceptor antagonists in benign prostatic hyperplasia: rationale and clinica] experience. Eur Urol 1996;29:129-44
59. Chapple CR, Chartier-Kastler E. Pharmacokinetic profile of tamsulosin OCAS. BJU Int 2006;99(Suppl 2):9-12
60. Michel MC, Korstanje C, Krauwinkel W, Kuipers M. The pharmacokinetic profile of tamsulosin oral controlled absorption system (OCAS®). Eur Urol 2005;4(2):15-24
61. Sako K, Mizumoto T, Kajiyama A, Ohmura T. Influence of physical factors in gastrointestinal tract on acetaminophen release from controlled-release tablets in fasted dogs. Int J Pharm 1996;137:225-32
62. Chapple CR, Lorenz J, Mortensen R, et al. Tamsulosin Oral Controlled Absorption System (OCAS) in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH): efficacy and tolerability in a phase 2b dose response study. Eur Urol Suppl 2005;4(2):25-32
63. Chapple CR, Al-Shukri SH, Gattengo B, et al. Tamsulosin Oral Controlled Absorption System in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH): Efficacy and tolerability in a placebo and active comparative controlled phase 3a study. Eur Urol Suppl 2005;4(2):33-44
64. Djavan B, Shrinin M, Davies J, Bolodeoku J. The impact of Tamsulosin Oral Controlled Absorption System (OCAS) on nocturia and the quality of sleep: preliminary results of a pilot study. Eur Urol Suppl 2005;4(2):61-8
65. Michel MC, Chapple CR. Comparison of the cardiovascular effects of Tamsulosin Oral Controlled Absorption system (OCAS) and Alfuzosin prolonged release (XL). Eur Urol 2006;49(3):501-9
66. Kloner RA, Jackson G, Emmick JT, et al. Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men. J Urol 2004;172(5 Pt 1):1935-40
67. Lucas MG, Stephenson TP, Nargund V. Tamsulosin in the management of patients with acute urinary retention from benign prostatic hyperplasia. BJU Int 2005;95:354-7
68. Tsui G, Gillan C, Pond C, et al. Posttreatment complications of early-stage prostate cancer patients: brachytherapy versus three-dimensional conformal radiation therapy. Cancer J 2005;11(2):122-32
69. Merrick GS, Butler WM, Wallner KE, et al. Prophylactic versus therapeutic alpha-blockers after permanent prostate brachytherapy. Urology 2002;60(4):650-5
70. Elshaikh MA, Ulchaker JC, Reddy CA, et al. Prophylactic tamsulosin (Flomax) in patients undergoing prostate 1251 brachytherapy for prostate carcinoma: final report of a double-blind placebo-controlled randomized study. Int J Radiat Oncol Biol Phys 2005;62(1):164-9
71. Lee SW, Liong ML, Yuen KH, et al. Chronic prostatitis/chronic pelvic pain syndrome: role of alpha blocker therapy. Urol Int 2007;78(2):97-105
72. Nickel JC, Narayan P, McKay J, Doyle C. Treatment of chronic prostatitis/ chronic pelvic pain syndrome with tamsulosin: a randomized double blind trial. J Urol 2004;171(4):1594-7
73. Alexander RB, Propett KJ, Schaeffer AJ. et al. Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: a randomized, double-blind trial. Ann Intern Med 2004;141:581-9
74. McVary KT. A review of combination therapy in patients with benign prostatic hyperplasia. Clin Ther 2007;29(3):387-98
75. Kaplan SA, Roehrborn CG, Rovner ES, et al. Tolterodine and tamsulosin for the treatment of men with lower urinary tract symptoms and overactive bladder. JAMA 2006;296:2319-28
76. Parsons JK, Hergan LA, Sakamoto K, Lakin C. Efficacy of alpha-blockers for the treatment of ureteral stones. J Urol 2007;177(3):983-7
77. Bhagat SK, Chacko NK, Kekre NS, et al. Is there a role for tamsulosin in shock wave lithotripsy for renal and ureteral calculi? J Urol 2007;177(6):2185-8
78. Gravina GL, Costa AM, Ronchi P, et al. Tamsulosin treatment increases clinical success rate of single extracorporeal shock wave lithotripsy of renal stones. Urology 2005;66(1):24-8
79. Beach MA, Mauro LS. Pharmacologic expulsive treatment of ureteral calculi. Ann Pharmacother 2006;40(7-8):1361-8
80. Abrams P, Amarenco G, Bakke A, et al.; European Tamsulosin Neurogenic Lower Urinary Tract Dysfunction Study Group. Tamsulosin: efficacy and safety in patients with neurogenic lower urinary tract dysfunction due to suprasacral spinal cord injury. J Urol 2003;170(4 Pt 1):1242-51
81. Kakizaki H, Ameda K, Kobayashi S, et al. Urodynamic effects of alpha1-blocker tamsulosin on voiding dysfunction in patients with neurogenic bladder. Int J Urol 2003;10(11):576-81
82. Michel MC. Alpha(1)-adrenoceptors and ejaculatory function. Br J Pharmacol 2007;152(3):289-90
83. van Dijk MM, de la Rosette JJ, Michel MC. Effects of α1-adrenoceptor antagonists on male sexual function. Drugs 2006; 66:287-301
84. Parssinen O, Leppanen E, Keski-Rahkonen P, et al. Influence of tamsulosin on the iris and its implications for cataract surgery. Invest Ophthalmol Vis Sci 2006;47:3766-71
85. Gurbaxani A, Packard R. Intracameral phenylephrine to prevent floppy iris syndrome during cataract surgery in patients on tamsulosin. Eye 2007;21(3):331-2
86. Chang DF, Campbell JR. Intraoperative floppy iris syndrome associated with tamsulosin. J Cataract Refract Surg 2005;31(4):664-73
87. Djavan B, Marberger M. A meta-analysis of the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999;36(1):1-13
88. Lowe FC. Alpha-1-adrenoceptor blockade in the treatment of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 1999;2:110-9
89. Lowe FC. Summary of clinical experiences with tamsulosin for the treatment of benign prostatic hyperplasia. Rev Urol 2005;7(4):513-21